Roles of 5-Hydroxytryptamine (5-HT) Receptor Subtypes in the Inhibitory Effects of 5-HT on C-Fiber Responses of Spinal Wide Dynamic Range Neurons in Rats
- Neuroscience Research Institute and Department of Neurobiology, Peking University, Key Laboratory for Neuroscience, Ministry of Education, Beijing, People's Republic of China
- Address correspondence to:
Dr. You Wan, Neuroscience Research Institute, Peking University, 38 Xue-Yuan Road, Beijing 100083, People's Republic of China. E-mail: ywan{at}bjmu.edu.cn
Abstract
5-Hydroxytryptamine (5-HT; serotonin) plays an important role in the descending control of nociception. 5-HT and its receptors have been extensively studied in the modulation of nociceptive transmission at the spinal level using behavioral tests that may be affected by the effects of 5-HT on motor performance and skin temperature. Using electrophysiological methods, the present study aimed to systematically investigate the roles of 5-HT receptor subtypes on the inhibitory effects of 5-HT on responses of the spinal wide dynamic range (WDR) neurons to C-fiber inputs in rats. Under basal conditions, topical application of 5-HT to the spinal cord inhibited the C-fiber responses of WDR neurons dose-dependently, whereas antagonists of 5-HT1A [WAY 100635 [N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-cyclohexanecarboxamide maleate salt]], 5-HT1B [GR 55562 [3-[3-(dimethylamino)propyl]-4-hydroxy-N-[4-(4-pyrid-dinyl)phenyl]benzamide dihydrochloride]], 5-HT2A [ketanserin [3-[2-[4-(fluorobenzoyl)-1-piperidinyl]ethyl]-2,4[1H,3H]-quinazolinedione tartrate]], 5-HT2C [RS 102221 [8-[5-(2,4-dimethoxy-5-(4-trifluoromethylphenylsulfonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride]], 5-HT3 [MDL 72222 [3-tropanyl-3,5-dichlorobenzoate]], and 5-HT4 [GR 113808 ([1-[2-[(methylsulfonyl)-amino]ethyl]-4-piperidinyl]methyl 1-methyl-1H-indole-3-carboxylate)] had no effect on their own. The inhibitory effects of 5-HT were reversed by antagonists of 5-HT1B (GR 55562), 5-HT2A (ketanserin), 5-HT2C (RS 102221), 5-HT3 (MDL 72222), and 5-HT4 (GR 113808) but not by 5-HT1A (WAY 100635) receptor antagonists. Topical administration of agonists of 5-HT1A [(2R)-(+)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide], 5-HT1B [CGS 12066 [7-trifluoromethyl-4-(4-methyl-1-piperazinyl)pyrrolo-[1,2-a]quinoxaline maleate salt]], 5-HT2A (α-methyl-5-hydroxytryptamine maleate), 5-HT2C [MK 212 [6-chloro-2-(1-piperazinyl)pyrazine hydrochloride]], 5-HT3 [1-(3-chlorophenyl)biguanide hydrochloride], and 5-HT4 [2-[1-(4-piperonyl)piperazinyl]benzothiazole] also inhibited the C-responses. These results suggest that, under basal conditions, there is no tonic serotonergic inhibition on the C-responses of dorsal horn neurons, and multiple 5-HT receptor subtypes including 1B, 2A, 2C, 3, and 4 may be involved in mediating the inhibitory effects of 5-HT.
Footnotes
-
This work was supported by the National Natural Science Foundation of China (Grants 30370470, 30470559, 30570566, 30330230, and 30600173) and by the Beijing Natural Science Foundation (Grant 7052039).
-
F.-Y.L. and G.-G.X. contributed equally to this work.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.106.115204.
-
ABBREVIATIONS: 5-HT, 5-hydroxytryptamine (serotonin); 8-OH-DPAT, (2R)-(+)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide; WDR, wide dynamic range; WAY 100635, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-cyclohexanecarboxamide maleate salt; GR 55562, 3-[3-(dimethylamino)propyl]-4-hydroxy-N-[4-(4-pyrid-dinyl)phenyl]benzamide dihydrochloride; ketanserin, 3-[2-[4-(fluorobenzoyl)-1-piperidinyl]ethyl]-2,4[1H,3H]-quinazolinedione tartrate; RS 102221, 8-[5-(2,4-dimethoxy-5-(4-trifluoromethylphenylsulfonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride; MDL 72222, 3-tropanyl-3,5-dichlorobenzoate; GR 113808, [1-[2-[(methylsulfonyl)-amino]-ethyl]-4-piperidinyl]methyl 1-methyl-1H-indole-3-carboxylate; CGS 12066, 7-trifluoromethyl-4-(4-methyl-1-piperazinyl)pyrrolo-[1,2-a]quinoxaline maleate salt; α-m-5-HT, α-methyl-5-hydroxytryptamine maleate; MK 212, 6-chloro-2-(1-piperazinyl)pyrazine hydrochloride; mCPBG, 1-(3-chlorophenyl)biguanide hydrochloride; BZTZ, 2-[1-(4-piperonyl)piperazinyl]benzothiazole; DMSO, dimethyl sulfoxide; NS, normal saline; ANOVA, analysis of variance.
-
- Received October 18, 2006.
- Accepted February 27, 2007.
- The American Society for Pharmacology and Experimental Therapeutics



